Night Eating Syndrome: Diagnostic Criteria, Treatment and GLP-1 Evidence

Night eating syndrome (NES) is an eating disorder in which food intake shifts late into the day: a person eats at least a quarter of their daily calories after the evening meal, wakes at night to eat at least twice a week, or both, and is aware of it and distressed by it ^[2]. It was first described in 1955 in people with obesity ^[1] and is now listed in DSM-5 as an “other specified feeding or eating disorder” ^[3]. It affects roughly 1% to 2% of the general population and more people with obesity ^[3][4]. This review covers the criteria, how NES differs from binge eating and sleep-related eating, what treatment trials show, and what is and is not known about GLP-1 drugs.

The honest summary

• It is defined by timing, not amount. The core is eating at least 25% of daily intake after dinner and/or waking to eat at least twice a week, with full awareness ^[2].
• It is more common with obesity. About 1.1% in a German population survey ^[3], versus 2.8% to 8.2% across obesity, eating-disorder and bariatric samples ^[4].
• It is not binge eating or sleepwalking. Night-time portions are usually snack-sized, unlike binges ^[4], and people remember eating, unlike sleep-related eating disorder ^[2].
• Sertraline has the best trial result. 71% responded versus 18% on placebo in an 8-week randomized trial ^[13]. Escitalopram did not beat placebo ^[14].
• Behavioral treatment helps in small studies. CBT and relaxation training reduced evening eating in pilots ^[15][16].
• GLP-1 drugs are untested in NES. Semaglutide lowered evening-meal and snack intake in people with obesity in a lab study ^[19], but that is not the same as treating the disorder.

Night eating syndrome diagnostic criteria

The criteria most studies use come from an international consensus published in 2010 ^[2]. They describe NES as a delay in the daily pattern of eating:

1. Core pattern (one or both): eating at least 25% of daily calories after the evening meal (evening hyperphagia), and/or at least two night-time awakenings per week with eating (nocturnal ingestions) ^[2].
2. Awareness: the person knows they are eating and remembers it the next day ^[2].
3. At least three of five features: little appetite in the morning; a strong urge to eat between dinner and bedtime or on waking at night; trouble falling or staying asleep; a belief that eating is needed to get back to sleep; and low mood that is worse in the evening ^[2].
4. Distress or impaired functioning, lasting at least three months, and not explained by another medical or psychiatric condition ^[2].

The 25% threshold was not arbitrary. In one-week food diaries, people with NES ate an average of 35% of their daily intake after the evening meal, compared with 10% in controls ^[2]. The original 1955 description by Stunkard and colleagues, in obese patients who were not responding to weight-loss treatment, already named the three hallmarks: morning loss of appetite, evening overeating and insomnia ^[1][2].

NES is a real eating disorder rather than a habit. A 2024 meta-analysis found that people with NES had levels of eating-disorder and general psychological symptoms comparable to those with full-threshold eating disorders, and higher than controls ^[10]. In the German population survey, screening positive for NES was linked to depression, anxiety, eating-disorder symptoms and higher body weight ^[3].

How common is night eating syndrome?

Figures vary with the definition and the tool used. In a representative sample of 2,460 Germans aged 14 to 85, 1.1% screened positive ^[3], and reviews put the general-population rate at about 1% to 2% ^[4]. Rates are higher in clinical groups: a systematic review limited to DSM-5 criteria found 2.8% to 8.2% across eating-disorder, obesity and bariatric-surgery populations ^[4][5], and a review of people with type 2 diabetes found 3.8% to 8.4% ^[9].

The link with weight is real but not simple. Prevalence is higher in obese populations and seems to rise with BMI ^[6], yet studies of NES and BMI remain mixed ^[4]. Self-report also inflates rates: among bariatric-surgery candidates, interview-confirmed NES was much less common than the self-reported figures ^[7]. Before bariatric surgery, 17.7% of 2,266 people in a large U.S. study reported night eating on a questionnaire ^[8]. NES symptoms tend to decrease after weight-loss surgery, and there is no evidence that having NES beforehand leads to worse weight loss afterward ^[6].

Night eating syndrome vs binge eating disorder

The two often occur together: between 18% and 50% of people with binge eating disorder also meet criteria for NES ^[4]. The differences are in the eating itself. A binge requires an objectively large amount of food with a sense of loss of control, while night-time eating in NES is usually the size of a snack or small meal ^[4]. Night eating is often driven by the wish to get back to sleep rather than by cravings or emotional distress, and a systematic review found that binge eating disorder involves more emotional eating and more concern about body shape ^[4][5]. For binge eating and GLP-1 drugs, see GLP-1 drugs and binge eating and GLP-1 drugs versus Vyvanse for binge eating disorder.

Night eating syndrome vs sleep-related eating disorder

Sleep-related eating disorder (SRED) is a parasomnia, a sleep disorder, rather than an eating disorder. The key difference is awareness. People with NES are awake and remember eating; people with SRED typically eat in a sleepwalking-like state, may have partial or complete amnesia for it, and sometimes eat odd or inedible things ^[2]. In practice the line can blur: when an eating-disorder specialist assessed 28 people diagnosed with SRED by a sleep expert, 22 also met NES criteria ^[11].

The distinction matters because SRED is often set off by medicines. In the World Health Organization’s adverse-event database, the drugs most strongly linked to SRED reports were zolpidem, sodium oxybate, suvorexant and quetiapine, along with some stimulants and SNRI antidepressants ^[12]. Night eating with poor memory of the episodes, especially after starting a sleep medicine, belongs with a sleep specialist.

Treatment: what the trials show

A 2025 systematic review found five randomized trials of NES treatment, testing sertraline, escitalopram, agomelatine and psychosocial programs such as education and relaxation training ^[18]. Sertraline showed the most consistent improvement, but small numbers and differing methods meant the certainty of evidence was rated low for every outcome.

Sertraline and other antidepressants

In an 8-week double-blind trial of 34 outpatients, sertraline (50 to 200 mg a day) led to a response in 71% of patients versus 18% on placebo ^[13]. It also reduced night-time awakenings and eating, calories eaten after the evening meal and overall severity, and improved quality of life. People with overweight or obesity on sertraline lost an average of 2.9 kg, versus 0.3 kg on placebo. A 12-week trial of escitalopram in 40 people did not beat placebo on the main night eating score, though both groups improved and more escitalopram patients were rated as responders (12 versus 7, not statistically significant) ^[14]. If you take an antidepressant alongside a GLP-1 drug, see GLP-1 drugs and SSRIs.

CBT, relaxation and light therapy

A 10-session cognitive behavioral therapy program in 25 patients cut the share of calories eaten after dinner from 35.0% to 24.9% and night-time eating episodes from 8.7 to 2.6 a week, with weight falling from 82.5 to 79.4 kg and mood improving ^[15]. There was no control group. In a small randomized pilot of 44 people, progressive muscle relaxation produced the largest drop in food eaten after the evening meal (about 31%), compared with education alone ^[16]. Two weeks of bright morning light reduced night eating symptoms in a 15-person uncontrolled pilot ^[17]. All three approaches are promising but need larger controlled trials.

Do GLP-1 drugs help night eating?

No trial has tested a GLP-1 drug in people diagnosed with night eating syndrome; the trials in the 2025 systematic review tested sertraline, escitalopram, agomelatine and psychosocial programs ^[18]. What does exist is evidence that these drugs reduce eating, including later in the day, in people with obesity:

• Evening meal and snacks. In a 12-week crossover trial of 30 people with obesity, semaglutide 1.0 mg lowered intake at a buffet lunch and at the following evening meal and snacks, cutting total intake across the day’s free-choice meals by 24% versus placebo. Hunger, food cravings and preference for high-fat foods fell, and control of eating improved ^[19].
• Higher dose. In a 20-week trial of semaglutide 2.4 mg in 72 adults with obesity, intake at a buffet lunch was 35% lower than with placebo, with better control of eating and fewer or weaker cravings ^[20].
• Eating behaviors more broadly. A 2026 rapid review of 25 studies found that binge eating episodes and food cravings generally improved or stayed the same on GLP-1 drugs, while noting that data on eating disorders are limited ^[21].

These findings make it plausible that a GLP-1 drug would reduce the amount eaten in the evening. They do not show that it would correct the delayed eating rhythm, the insomnia, the night-time waking or the evening low mood that define NES. Eating-disorder researchers have also raised concern that GLP-1 drugs could cause unintended harm or be misused by some people with eating disorders, and recommend careful assessment before and during treatment ^[22]. Because poor morning appetite is already one of the NES features ^[2], it is worth making sure total intake stays adequate on an appetite-suppressing drug; our guide on eating too little on a GLP-1 covers the warning signs.

Practical guidance

• Track the timing for a week. If a quarter or more of your food comes after dinner, or you wake to eat twice a week or more, that matches the NES pattern ^[2].
• Notice whether you remember it. Eating you do not recall, especially after a new sleep medicine, points toward sleep-related eating disorder ^[2][12].
• Ask about tested treatments. Sertraline has the strongest trial result; CBT and relaxation training have encouraging pilot data ^[13][15][16].
• Do not expect a GLP-1 to fix the rhythm. It may lower how much you eat, but it has not been studied for NES ^[18][19].
• Mention night eating before weight-loss surgery. It is common in surgical candidates and tends to improve afterward ^[6].